A dietary supplement promoted as selling big in Germany as a cold sore remedy could test US regulations as it launches with claims including “acts as an antiviral, stopping viral reproduction” and “promotes faster wound healing.”
Cold Sore Supplement From Germany Reaches US
Linpharma Bioactives is US marketer of Lyranda brand chewable lozenge made by German firm Weber & Weber International. Online claims include “acts as an antiviral, stopping viral reproduction.”

More from Regulation
“It's kind of a free for all,” says longtime FDA funding advocate Steven Grossman. FDA knew funding it requested “was totally inadequate to the needs. So, Food Chemical Safety is stuck there with about six or eight other purposes the money could have been used for.
CRN petition argues against general preclusion while NPA petition addressed specifically FDA’s wielding of the provision to prohibit the use of NMN supplements available in US. “FDA has acknowledged that they really can't answer one without answering. The two are inextricably linked,” says CRN CEO Steve Mister.
Supplements already under close scrutiny in the EU have been linked to severe adverse effects on the musculoskeletal system and liver, even at low doses.
UK industry association is offering online courses on subjects ranging from UK medicines regulations basics to deep dives on complex topics such as CBD.
More from Innovation & IP
Biotech identifying and stabilizing RNA compounds that can be incorporated into dietary supplements will receive mentorship, strategy guidance and technical support from experts at Nestlé Health Science.
With the acquisition of HKS Health Solutions, 1Q Health Group states its ambition to be the leading full-service CDMO in Europe. Separately, Italy's Ourvita enhances its capabilities through a deal for Poland's Laboratoria Natury.
Increased openness about sexual health and wellness, Rx-to-OTC switches and NPD at leading companies, and easy access to products online are driving the growth of Europe's sexual health market, according to Euromonitor International.